 The first cohort n4 of patients will be treated with NGR-hTNF administered at 60 mcgm2 IV every three weeks, that is a dose level 33 higher than MTD and recommended dose selected in the previous phase I trial i.e., 45 mcgm2. If 1 of 4 patients experience DLT during the first cycle, following cohorts will be treated with escalating doses from 80 to 325 mcgm2 of NGR-hTNF IV every three weeks. 